Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lee Mozessohn

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Blood Advances|May 2, 2025
Finding the right fit: assessment of fitness in AMLNicholas Chornenki, Lee Mozessohn
Haematologica|June 26, 2025
Should we move past erythropoietin-stimulating agent monotherapy in lower-risk myelodysplastic syndromes?Lee Mozessohn, Rena Buckstein
Leukemia & Lymphoma|July 1, 2024
Cytomegalovirus infection risk with alemtuzumab therapy in hematological malignancies: a retrospective cohort study in the non-transplant settingJoel George, Lee Mozessohn, Philip W Lam
BMJ Case Reports|July 12, 2012
Polyneuropathy: a poetic diagnosisReena Pattani, Dmitry Rozenberg, Lee Mozessohn, et al.
British Journal of Clinical Pharmacology|March 18, 2025
Severe myelosuppression and alopecia after thiopurine initiation in a patient with NUDT15 deficiencyAnnie Siyu Wu, Lee Mozessohn, Richard B Kim, et al.
Blood Advances|November 29, 2023
A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AMLMithunan Ravindran, Lee Mozessohn, Matthew Cheung, et al.
Annals of Hematology|November 28, 2022
EBV-positive diffuse large B-cell lymphoma following alemtuzumab therapy for T-cell prolymphocytic leukemiaAdam Suleman, Hubert Tsui, Zeina Ghorab, et al.
Sexually Transmitted Diseases|October 6, 2005
Factors affecting knowledge of sexually transmitted infection transmissibility in healthcare providers: results from a national surveyNatalie O Rosen, Bärbel Knäuper, Lee Mozessohn, et al.
Journal of the National Cancer Institute|October 22, 2016
The Association of Dyslipidemia With Chronic Lymphocytic Leukemia: A Population-Based StudyLee Mozessohn, Craig Earle, David Spaner, et al.
Leukemia & Lymphoma|February 11, 2020
Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the 'real-world'Lee Mozessohn, Matthew C Cheung, Nicole Mittmann, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Blood Advances|May 2, 2025
Finding the right fit: assessment of fitness in AMLNicholas Chornenki, Lee Mozessohn
Haematologica|June 26, 2025
Should we move past erythropoietin-stimulating agent monotherapy in lower-risk myelodysplastic syndromes?Lee Mozessohn, Rena Buckstein
Leukemia & Lymphoma|July 1, 2024
Cytomegalovirus infection risk with alemtuzumab therapy in hematological malignancies: a retrospective cohort study in the non-transplant settingJoel George, Lee Mozessohn, Philip W Lam
BMJ Case Reports|July 12, 2012
Polyneuropathy: a poetic diagnosisReena Pattani, Dmitry Rozenberg, Lee Mozessohn, et al.
British Journal of Clinical Pharmacology|March 18, 2025
Severe myelosuppression and alopecia after thiopurine initiation in a patient with NUDT15 deficiencyAnnie Siyu Wu, Lee Mozessohn, Richard B Kim, et al.
Blood Advances|November 29, 2023
A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AMLMithunan Ravindran, Lee Mozessohn, Matthew Cheung, et al.
Annals of Hematology|November 28, 2022
EBV-positive diffuse large B-cell lymphoma following alemtuzumab therapy for T-cell prolymphocytic leukemiaAdam Suleman, Hubert Tsui, Zeina Ghorab, et al.
Sexually Transmitted Diseases|October 6, 2005
Factors affecting knowledge of sexually transmitted infection transmissibility in healthcare providers: results from a national surveyNatalie O Rosen, Bärbel Knäuper, Lee Mozessohn, et al.
Journal of the National Cancer Institute|October 22, 2016
The Association of Dyslipidemia With Chronic Lymphocytic Leukemia: A Population-Based StudyLee Mozessohn, Craig Earle, David Spaner, et al.
Leukemia & Lymphoma|February 11, 2020
Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the 'real-world'Lee Mozessohn, Matthew C Cheung, Nicole Mittmann, et al.
Pageof 5